Perspectives of modeling and simulation in Japan

Research output: Contribution to journalShort survey

Abstract

The usefulness of model-based drug development using modeling and simulation (M&S) techniques has been recognized recently in Japan. However, few real examples of M&S have been conducted in Japan. This paucity is caused by two factors : 1) there are not so many 'pharmacometricians' who are responsible for planning, conducting and presenting M&S ; and 2) the infrastructure required by M&S is not well developed. To address the former problem, well presented textbooks for self-learning are needed for beginners and even for experienced pharmacokineticists with little background of biostatistics, and vice versa. The problem of poor infrastructure for M&S in Japan is more serious. For example, disease progression models for diseases that are considered to show different pathology in Japanese and Caucasians, such as diabetes mellitus, are urgently needed to predict the progression of the disease and to facilitate the development of new drugs in Japan. Pharmacometricians including pharmacokineticists, biostatisticians, and clinical pharmacologists have to collaborate with each other to solve these problems and contribute to the public health of Japan by ensuring development of new effective and safe drug compounds.

Original languageEnglish
Pages (from-to)211-215
Number of pages5
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume41
Issue number5
DOIs
Publication statusPublished - 2010 Sep
Externally publishedYes

Fingerprint

Japan
Disease Progression
Biostatistics
Pharmaceutical Preparations
Textbooks
Diabetes Mellitus
Public Health
Learning
Pathology

Keywords

  • Disease model
  • Modeling & simulation
  • Pharmacometrics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Perspectives of modeling and simulation in Japan. / Kasai, Hidefumi.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 41, No. 5, 09.2010, p. 211-215.

Research output: Contribution to journalShort survey

@article{8cf64fd7cc6e4aea91ff6787422d0c6f,
title = "Perspectives of modeling and simulation in Japan",
abstract = "The usefulness of model-based drug development using modeling and simulation (M&S) techniques has been recognized recently in Japan. However, few real examples of M&S have been conducted in Japan. This paucity is caused by two factors : 1) there are not so many 'pharmacometricians' who are responsible for planning, conducting and presenting M&S ; and 2) the infrastructure required by M&S is not well developed. To address the former problem, well presented textbooks for self-learning are needed for beginners and even for experienced pharmacokineticists with little background of biostatistics, and vice versa. The problem of poor infrastructure for M&S in Japan is more serious. For example, disease progression models for diseases that are considered to show different pathology in Japanese and Caucasians, such as diabetes mellitus, are urgently needed to predict the progression of the disease and to facilitate the development of new drugs in Japan. Pharmacometricians including pharmacokineticists, biostatisticians, and clinical pharmacologists have to collaborate with each other to solve these problems and contribute to the public health of Japan by ensuring development of new effective and safe drug compounds.",
keywords = "Disease model, Modeling & simulation, Pharmacometrics",
author = "Hidefumi Kasai",
year = "2010",
month = "9",
doi = "10.3999/jscpt.41.211",
language = "English",
volume = "41",
pages = "211--215",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "5",

}

TY - JOUR

T1 - Perspectives of modeling and simulation in Japan

AU - Kasai, Hidefumi

PY - 2010/9

Y1 - 2010/9

N2 - The usefulness of model-based drug development using modeling and simulation (M&S) techniques has been recognized recently in Japan. However, few real examples of M&S have been conducted in Japan. This paucity is caused by two factors : 1) there are not so many 'pharmacometricians' who are responsible for planning, conducting and presenting M&S ; and 2) the infrastructure required by M&S is not well developed. To address the former problem, well presented textbooks for self-learning are needed for beginners and even for experienced pharmacokineticists with little background of biostatistics, and vice versa. The problem of poor infrastructure for M&S in Japan is more serious. For example, disease progression models for diseases that are considered to show different pathology in Japanese and Caucasians, such as diabetes mellitus, are urgently needed to predict the progression of the disease and to facilitate the development of new drugs in Japan. Pharmacometricians including pharmacokineticists, biostatisticians, and clinical pharmacologists have to collaborate with each other to solve these problems and contribute to the public health of Japan by ensuring development of new effective and safe drug compounds.

AB - The usefulness of model-based drug development using modeling and simulation (M&S) techniques has been recognized recently in Japan. However, few real examples of M&S have been conducted in Japan. This paucity is caused by two factors : 1) there are not so many 'pharmacometricians' who are responsible for planning, conducting and presenting M&S ; and 2) the infrastructure required by M&S is not well developed. To address the former problem, well presented textbooks for self-learning are needed for beginners and even for experienced pharmacokineticists with little background of biostatistics, and vice versa. The problem of poor infrastructure for M&S in Japan is more serious. For example, disease progression models for diseases that are considered to show different pathology in Japanese and Caucasians, such as diabetes mellitus, are urgently needed to predict the progression of the disease and to facilitate the development of new drugs in Japan. Pharmacometricians including pharmacokineticists, biostatisticians, and clinical pharmacologists have to collaborate with each other to solve these problems and contribute to the public health of Japan by ensuring development of new effective and safe drug compounds.

KW - Disease model

KW - Modeling & simulation

KW - Pharmacometrics

UR - http://www.scopus.com/inward/record.url?scp=78349289612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349289612&partnerID=8YFLogxK

U2 - 10.3999/jscpt.41.211

DO - 10.3999/jscpt.41.211

M3 - Short survey

AN - SCOPUS:78349289612

VL - 41

SP - 211

EP - 215

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 5

ER -